目的: 涎液化糖链抗原6（krebs von den lungen-6,KL-6）是一种主要由II型肺泡上皮细胞和分泌的糖蛋白,血液中KL-6水平与新冠病毒感染患者严重程度似乎存在相关性。因此,我们进行了荟萃分析,旨在评估血清KL-6水平在判定新冠病毒感染患者严重程度中的作用。方法: 在PubMed、the Cochrane Library、中国知网（CNKI）、万方医学数据库检索2019年12月—2022年12月的相关文献。共纳入9项研究,随后使用RevMan 5.4及Stata 17.0进行汇总整合及分析。结果: 9项研究中重症患者的血清KL-6显著高于轻中症患者（SMD=1.14,95%CI：0.79~1.49）。4项研究中计算的综合诊断参数为：灵敏度0.63（95%CI：0.51~0.75）;特异度0.88（95%CI：0.84~0.91）;阳性似然比为5.23（95%CI：3.99~6.85）;阴性似然比0.42（95%CI：0.30~0.57）;受试者工作特征曲线下面积：0.87。结论: 在新冠病毒感染病程较重的患者中,KL-6水平显著升高,这表明KL-6可能是识别严重新冠病毒感染患者风险的有效检测指标。
Abstract
Objective Krebs von den Lungen-6(KL-6) is a glycoprotein mainly secreted by type II alveolar epithelial cells. Blood levels of KL-6 appear to be correlated with the severity of COVID-19 patients. Therefore, we conducted a meta-analysis in this paper to assess the role of serum KL-6 levels in determining the severity of COVID-19 patients. Methods The relevant literatures from December 2019 to December 2022 were searched in PUBMED, the Cochrane Library, CNKI and Wanfang Medical database. A total of 9 studies were included and pooled in the meta-analysis. Use RevMan 5.4 and Stata 17.0 for summary, integration and analysis. Results Serum KL-6 in severe patients was significantly higher than that in mild patients in 9 studies (SMD=1.14, 95%CI: 0.79-1.49). The composite diagnostic parameters calculated in the four studies were sensitivity 0.63(95% CI: 0.51 - 0.75), specificity 0.88(95% CI: 0.84 - 0.91), positive likelihood ratio 5.23(95% CI: 3.99- 6.85), negative likelihood ratio 0.42(95% CI: 0.30 - 0.57), and area under the receiver operating characteristic curve 0.87. Conclusion KL-6 levels were significantly elevated in patients with a more advanced course of COVID-19, suggesting that KL-6 may be an effective test for identifying risk in patients with severe COVID-19.
关键词
涎液化糖链抗原6 /
新冠病毒感染 /
荟萃分析
Key words
krebs von den lungen-6 /
COVID-19 /
meta-analysis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ahn DG, Shin HJ, Kim MH, et al.Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019(COVID-19)[J]. J Microbiol Biotechnol, 2020, 30(3): 313-324.
[2] Amor S, Fernández Blanco L, Baker D.Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage[J]. Clin Exp Immunol, 2020, 202(2): 193-209.
[3] Kirtipal N, Bharadwaj S, Kang SG.From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses[J]. Infect Genet Evol, 2020, 85: 104502.
[4] Carsana L, Sonzogni A, Nasr A, et al.Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study[J]. Lancet Infect Dis, 2020, 20(10): 1135-1140.
[5] Tjendra Y, Al Mana AF, Espejo AP, et al.Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers[J]. Arch Pathol Lab Med, 2020, 144(12): 1465-1474.
[6] Yamakawa H, Hagiwara E, Ikeda S, et al.Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia[J]. Respir Investig, 2019, 57(5): 422-429.
[7] Chen H, Qin R, Huang Z, et al.Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019[J]. Cytokine, 2021, 148: 155513.
[8] Luo D, Wan X, Liu J, et al.Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range[J]. Stat Methods Med Res, 2018, 27(6): 1785-1805.
[9] Awano N, Inomata M, Kuse N, et al.Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019[J]. Respir Investig, 2020, 58(6): 440-447.
[10] Bergantini L, Bargagli E, d'Alessandro M, et al. Prognostic bioindicators in severe COVID-19 patients[J]. Cytokine, 2021, 141: 155455.
[11] Chen H, Qin R, Huang Z, et al.Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019[J]. Cytokine, 2021, 148: 155513.
[12] d'Alessandro M, Cameli P, Refini RM, et al. Serum KL-6 concentrations as a novel biomarker of severe COVID-19[J]. J Med Virol, 2020, 92(10): 2216-2220.
[13] d'Alessandro M, Bergantini L, Cameli P, et al. Peripheral biomarkers' panel for severe COVID-19 patients[J]. J Med Virol, 2021, 93(3): 1230-1232.
[14] Deng K, Fan Q, Yang Y, et al.Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis[J]. J Med Virol, 2021, 93(4): 2505-2512.
[15] Peng DH, Luo Y, Huang LJ, et al.Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019[J]. Clin Chim Acta, 2021, 517: 48-53.
[16] Xue M, Zhang T, Chen H, et al.Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients[J]. Int J Biol Sci, 2021, 17(6): 1565-1573.
[17] Yamaya T, Hagiwara E, Baba T, et al.Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019[J]. Respir Investig, 2021, 59(5): 596-601.
[18] 史河水, 韩小雨, 樊艳青, 等. 新型冠状病毒 (2019-nCoV) 感染的肺炎临床特征及影像学表现[J]. 临床放射学杂志, 2020, 39(01): 8-11.
[19] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[20] Xu Z, Shi L, Wang Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
[21] Fotoh DS, Helal A, Rizk MS, et al.Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease[J]. Clin Rheumatol, 2021, 40(7): 2689-2697.
[22] Jee AS, Sahhar J, Youssef P, et al.Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons[J]. Pharmacol Ther, 2019, 202: 40-52.
[23] Kumánovics G, Görbe E, Minier T, et al. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis[J]. Clin Exp Rheumatol, 2014, 32(6 Suppl 86): S-138-144.
[24] Gomes AMC, Farias GB, Dias-Silva M, et al.SARS-CoV2 pneumonia recovery is linked to expansion of innate lymphoid cells type 2 expressing CCR10[J]. Eur J Immunol, 2021, 51(12): 3194-3201.
PDF(3010 KB)
